{"id":47306,"date":"2022-08-15T22:01:41","date_gmt":"2022-08-15T20:01:41","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/babylon-denies-acquisition-rumors\/"},"modified":"2022-08-15T22:01:41","modified_gmt":"2022-08-15T20:01:41","slug":"babylon-denies-acquisition-rumors","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/babylon-denies-acquisition-rumors\/","title":{"rendered":"Babylon Denies Acquisition Rumors"},"content":{"rendered":"
\n

AUSTIN, Texas & LONDON–(BUSINESS WIRE)–Babylon Holdings Limited (NYSE: BBLN) (\u201cBabylon\u201d or the \u201cCompany\u201d)<\/b>, one of the world\u2019s fastest-growing digital healthcare companies, today announced that it is not engaged in nor has it had contact or discussions with any potential acquirer.\n<\/p>\n

<\/a><\/p>\n

\nThe Company is actively working with the staff of the NYSE to resume trading as soon as possible.\n<\/p>\n

\nAbout Babylon<\/span><\/b>\n<\/p>\n

\nBabylon is one of the world\u2019s fastest growing digital healthcare companies whose mission is to make high-quality healthcare accessible and affordable for every person on Earth.\n<\/p>\n

\nBabylon is re-engineering how people engage with their care at every step of the healthcare continuum. By flipping the model from reactive sick care to proactive healthcare through the devices people already own, it offers millions of people globally ongoing, always-on care. Babylon has already shown that in environments as diverse as the developed UK or developing Rwanda, urban New York or rural Missouri, for people of all ages, it is possible to achieve its mission by leveraging its highly scalable, digital-first platform combined with high quality, virtual clinical operations to provide integrated, personalized healthcare.\n<\/p>\n

\nBabylon is re-engineering how people engage with their care at every step of the healthcare continuum. By flipping the model from reactive sick care to proactive healthcare through the devices people already own, it offers 24 million people globally ongoing, always-on care. Babylon has already shown that in environments as diverse as the developed UK or developing Rwanda, urban New York or rural Missouri, for children on Medicaid, or the elderly on Medicare, it is possible to achieve its mission by leveraging its highly scalable, digital-first platform combined with high quality, virtual clinical operations to provide integrated, personalized healthcare.\n<\/p>\n

\nFounded in 2013, Babylon\u2019s technology and clinical services is supporting a global patient network across 15 countries, and is capable of operating in 16 languages. And through a combination of its value-based care model, Babylon 360, and its work in primary care through NHS GP at Hand, Babylon managed over 440k lives globally from the start of 2022. In 2021 alone, Babylon helped a patient every 6 seconds, with approximately 5.2 million consultations and AI interactions. Importantly, this was achieved with a 93% user retention rate in our NHS GP at Hand service and 4 or 5 star ratings from more than 90% of our users across all of our geographies.\n<\/p>\n

\nBabylon is also working with governments, health providers, employers and insurers across the globe to provide them with a new infrastructure that any partner can use to deliver high-quality healthcare with lower costs and better outcomes. For more information, please visit www.babylonhealth.com<\/a><\/span>.\n<\/p>\n

\nForward-Looking Statements<\/span><\/b>\n<\/p>\n

\nThis press release contains \u201cforward-looking statements\u201d as defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements generally relate to future events or our future financial or operating performance. When used in this press release, the words \u201cestimates,\u201d \u201cprojected,\u201d \u201cexpects,\u201d \u201canticipates,\u201d \u201cforecasts,\u201d \u201cplans,\u201d \u201cintends,\u201d \u201cbelieves,\u201d \u201cseeks,\u201d \u201cmay,\u201d \u201cwill,\u201d \u201cshould,\u201d \u201cfuture,\u201d \u201cpropose\u201d and variations of these words or similar expressions (or the negative versions of such words or expressions) are intended to identify forward-looking statements. These forward-looking statements include, without limitation, information concerning Babylon\u2019s possible or assumed future results of operations, business strategies, debt levels, competitive position, industry environment and potential growth opportunities.\n<\/p>\n

\nThese forward-looking statements are not guarantees of future performance, conditions, or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside of Babylon\u2019s management\u2019s control, that could cause actual results to differ materially from the results discussed in the forward-looking statements. These risks, uncertainties, assumptions and other important factors include, but are not limited to our future financial and operating results and that we may require additional financing; uncertainties related to our ability to continue as a going concern; the growth of our business and organization; our failure to compete successfully; our ability to renew contracts with existing customers, and risks of contract renewals at lower fee levels, or significant reductions in members, pricing or premiums under our contracts due to factors outside our control; our dependence on our relationships with physician-owned entities; our ability to maintain and expand a network of qualified providers; our ability to increase engagement of individual members or realize the member healthcare cost savings that we expect; a significant portion of our revenue comes from a limited number of customers; the uncertainty and potential inadequacy of our claims liability estimates for medical costs and expenses; risks associated with estimating the amount and timing of revenue recognized under our licensing agreements and value-based care agreements with health plans; risks associated with our physician partners\u2019 failure to accurately, timely and sufficiently document their services; risks associated with inaccurate or unsupportable information regarding risk adjustment scores of members in records and submissions to health plans; risks associated with reduction of reimbursement rates paid by third-party payers or federal or state healthcare programs; risks associated with regulatory proposals directed at containing or lowering the cost of healthcare, including the ACO REACH model; immaturity and volatility of the market for telemedicine and our unproven digital-first approach; our ability to develop and release new solutions and services; the impact of COVID-19 or any other pandemic, epidemic or outbreak of an infectious disease in the United States or worldwide on our business; and the other risks and uncertainties identified in Babylon\u2019s Annual Report on Form 20-F filed with the SEC on March 30, 2022, and in other documents filed or to be filed by Babylon with the SEC and available at the SEC\u2019s website at www.sec.gov<\/a><\/span>.\n<\/p>\n

\nBabylon cautions that the foregoing list of factors is not exclusive and cautions readers not to place undue reliance upon any forward-looking statements, which speak only as of the date made. Except as required by law, Babylon does not undertake any obligation to update or revise its forward-looking statements to reflect events or circumstances after the date of this press release.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nMedia<\/i>
press@babylonhealth.com<\/a><\/p>\n

Investors<\/i>
investors@babylonhealth.com<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

AUSTIN, Texas & LONDON–(BUSINESS WIRE)–Babylon Holdings Limited (NYSE: BBLN) (\u201cBabylon\u201d or the \u201cCompany\u201d), one of the world\u2019s fastest-growing digital healthcare companies, today announced that it is not engaged in nor has it had contact or discussions with any potential acquirer. The Company is actively working with the staff of the NYSE to resume trading as … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-47306","6":"format-standard","7":"category-industry"},"yoast_head":"\nBabylon Denies Acquisition Rumors - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/babylon-denies-acquisition-rumors\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Babylon Denies Acquisition Rumors - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"AUSTIN, Texas & LONDON–(BUSINESS WIRE)–Babylon Holdings Limited (NYSE: BBLN) (\u201cBabylon\u201d or the \u201cCompany\u201d), one of the world\u2019s fastest-growing digital healthcare companies, today announced that it is not engaged in nor has it had contact or discussions with any potential acquirer. The Company is actively working with the staff of the NYSE to resume trading as ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/babylon-denies-acquisition-rumors\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-08-15T20:01:41+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20220815005673\/en\/1544640\/21\/Babylon_Logo_Horizontal_Violet_CMYK.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/babylon-denies-acquisition-rumors\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/babylon-denies-acquisition-rumors\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Babylon Denies Acquisition Rumors\",\"datePublished\":\"2022-08-15T20:01:41+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/babylon-denies-acquisition-rumors\\\/\"},\"wordCount\":996,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/babylon-denies-acquisition-rumors\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220815005673\\\/en\\\/1544640\\\/21\\\/Babylon_Logo_Horizontal_Violet_CMYK.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/babylon-denies-acquisition-rumors\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/babylon-denies-acquisition-rumors\\\/\",\"name\":\"Babylon Denies Acquisition Rumors - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/babylon-denies-acquisition-rumors\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/babylon-denies-acquisition-rumors\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220815005673\\\/en\\\/1544640\\\/21\\\/Babylon_Logo_Horizontal_Violet_CMYK.jpg\",\"datePublished\":\"2022-08-15T20:01:41+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/babylon-denies-acquisition-rumors\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/babylon-denies-acquisition-rumors\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/babylon-denies-acquisition-rumors\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220815005673\\\/en\\\/1544640\\\/21\\\/Babylon_Logo_Horizontal_Violet_CMYK.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220815005673\\\/en\\\/1544640\\\/21\\\/Babylon_Logo_Horizontal_Violet_CMYK.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/babylon-denies-acquisition-rumors\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Babylon Denies Acquisition Rumors\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Babylon Denies Acquisition Rumors - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/babylon-denies-acquisition-rumors\/","og_locale":"en_US","og_type":"article","og_title":"Babylon Denies Acquisition Rumors - Pharma Trend","og_description":"AUSTIN, Texas & LONDON–(BUSINESS WIRE)–Babylon Holdings Limited (NYSE: BBLN) (\u201cBabylon\u201d or the \u201cCompany\u201d), one of the world\u2019s fastest-growing digital healthcare companies, today announced that it is not engaged in nor has it had contact or discussions with any potential acquirer. The Company is actively working with the staff of the NYSE to resume trading as ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/babylon-denies-acquisition-rumors\/","og_site_name":"Pharma Trend","article_published_time":"2022-08-15T20:01:41+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20220815005673\/en\/1544640\/21\/Babylon_Logo_Horizontal_Violet_CMYK.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/babylon-denies-acquisition-rumors\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/babylon-denies-acquisition-rumors\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Babylon Denies Acquisition Rumors","datePublished":"2022-08-15T20:01:41+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/babylon-denies-acquisition-rumors\/"},"wordCount":996,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/babylon-denies-acquisition-rumors\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220815005673\/en\/1544640\/21\/Babylon_Logo_Horizontal_Violet_CMYK.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/babylon-denies-acquisition-rumors\/","url":"https:\/\/pharma-trend.com\/en\/babylon-denies-acquisition-rumors\/","name":"Babylon Denies Acquisition Rumors - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/babylon-denies-acquisition-rumors\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/babylon-denies-acquisition-rumors\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220815005673\/en\/1544640\/21\/Babylon_Logo_Horizontal_Violet_CMYK.jpg","datePublished":"2022-08-15T20:01:41+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/babylon-denies-acquisition-rumors\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/babylon-denies-acquisition-rumors\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/babylon-denies-acquisition-rumors\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20220815005673\/en\/1544640\/21\/Babylon_Logo_Horizontal_Violet_CMYK.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20220815005673\/en\/1544640\/21\/Babylon_Logo_Horizontal_Violet_CMYK.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/babylon-denies-acquisition-rumors\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Babylon Denies Acquisition Rumors"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/47306","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=47306"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/47306\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=47306"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=47306"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=47306"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}